Obstructive sleep apnea (OSA) is increasingly recognized as an independent cardiovascular risk factor. Yet most health systems have been slow to act on this. This article traces the growing, and still underutilized, role of sleep in cardiovascular care: The biological pathways linking OSA to heart disease, the evolving frameworks for understanding it, and the gap between scientific evidence and clinical implementation.
This article examines how obstructive sleep apnea (OSA) is incorporated into cardiovascular disease prevention, screening, and treatment frameworks, reviewing how — and whether — that recognition translates into clinical pathways.
Obstructive sleep apnea (OSA) is increasingly recognized as a cardiovascular risk factor — but how far has that recognition traveled into the prevention frameworks that shape clinical care? This article examines cardiovascular prevention guidelines across six health systems and finds that sleep remains largely absent or peripheral. The gap between clinical evidence and prevention policy remains substantial.
A comparison of six health systems — the United Kingdom, France, Germany, the United States, Australia, and Japan — reveals a consistent pattern: Despite radically different healthcare models, all exclude sleep disorders from chronic disease frameworks. OSA is managed episodically through device provision rather than long-term care pathways. The consistency of this pattern across systems suggests a structural design issue rather than a local policy failure, and points toward the need for OSA reclassification as a chronic condition requiring continuous management.
Sleep disorders are among the most prevalent medical conditions globally; obstructive sleep apnea (OSA) alone affects nearly 1 billion adults yet remains structurally invisible within most health systems. Across six countries, a consistent pattern emerges: Despite strong clinical evidence linking OSA and other sleep disorders to cardiovascular disease, diabetes, and premature mortality, sleep health remains peripheral to chronic disease frameworks, prevention strategies, and long-term care pathways. This is not a gap in the evidence. It is a gap in policy recognition.
Patients with obstructive sleep apnea (OSA) fall out of care at four predictable stages: Delayed or missed diagnosis, barriers to treatment initiation, therapy drop-off due to adherence challenges, and the absence of pathways back into care once treatment stops. This is not primarily a clinical failure, it is a structural one.
Despite strong biological evidence linking obstructive sleep apnea (OSA) to cardiovascular disease, integration into cardiovascular care pathways remains inconsistent across health systems. This article synthesizes findings from a Sleep Institute comparative analysis of six major health systems, identifies three distinct models of integration — siloed, partial and condition-specific, and systematic — and considers what more integrated care could involve. A key finding: The case for integration extends beyond the direct cardiovascular effects of positive airway pressure (PAP) therapy to risk stratification, blood pressure management, and care coordination.
The communities carrying the greatest burden of poor sleep are often the least likely to receive a diagnosis or treatment. As research on sleep and cognitive health develops, that gap deserves greater attention as a potential contributor to wider brain-health inequities.
The relationship between sleep disorders and cognitive health has become an important focus of brain health research. Sleep disorders are associated with a significantly higher risk of Alzheimer's disease and all-cause dementia, and the biological mechanisms involving the brain's own waste-clearance system are increasingly better understood.
GLP-1/GIP therapies are reshaping OSA care, but their arrival has exposed a critical guideline gap. Current guidelines lack operational direction on reassessment, multimodal sequencing and therapy discontinuation, risking unverified disease resolution assumptions and unsafe therapy abandonment.
At World Sleep 2025, international experts shared firsthand insights on what's broken and what's working in global OSA diagnosis. Hear the discussion on tackling missed diagnosis, challenging outdated norms and building new models of care.
Obstructive sleep apnea (OSA) is biologically heterogeneous, and distinct phenotypes show different treatment responses and adherence patterns. The current uniform, AHI‑driven care is misaligned with how the disease actually presents in many patients.
